1-4 of 4
Miyuki Takatori
Close
Sort by
Journal Articles

Amlexanox As a Possible Breakthrough Drug for MLL/AF4 -Positive Acute Lymphoblastic Leukemia

Hayato Tamai, MD PhD, Hiroki Yamaguchi, MD PhD, Koichi Miyake, MD PhD, Miyuki Takatori, Tomoaki Kitano, Syunsuke Yui, MD, Keiko Fukunaga, MD, Kazutaka Nakayama, MD PhD, Koiti Inokuchi, PhD MD
Journal: Blood
Blood (2016) 128 (22): 1590.
https://doi.org/10.1182/blood.V128.22.1590.1590
Published: 2016
Journal Articles

AAV8 vector expressing IL24 efficiently suppresses tumor growth mediated by specific mechanisms in MLL/AF4 -positive ALL model mice

Hayato Tamai, Koichi Miyake, Hiroki Yamaguchi, Miyuki Takatori, Kazuo Dan, Koiti Inokuchi, Takashi Shimada
Journal: Blood
Blood (2012) 119 (1): 64–71.
https://doi.org/10.1182/blood-2011-05-354050
Published: 2012
Includes: Supplemental data
Journal Articles

The Activated K-RAS Protein Accelerates Human Derived-MLL/AF4 Induced Leukemo-Lymphomogenicity In Transgenic Mice Model

Hayato Tamai, MD, Koichi Miyake, MD, PhD, Miyuki Takatori, Noriko Miyake, Hiroki Yamaguchi, MD, PhD, Kazuo Dan, MD, PhD, Takashi Shimada, MD, PHD, Koiti Inokuchi, PhD, MD
Journal: Blood
Blood (2010) 116 (21): 61.
https://doi.org/10.1182/blood.V116.21.61.61
Published: 2010
Journal Articles

Myeloproliferative disease in transgenic mice expressing P230 Bcr/Abl: longer disease latency, thrombocytosis, and mild leukocytosis

Brief Report
Koiti Inokuchi, Kazuo Dan, Miyuki Takatori, Hidemasa Takahuji, Naoya Uchida, Mitsuharu Inami, Koichi Miyake, Hiroaki Honda, Hisamaru Hirai, Takashi Shimada
Journal: Blood
Blood (2003) 102 (1): 320–323.
https://doi.org/10.1182/blood-2002-10-3182
Published: 2003